Send me a link:

*Only U.S. numbers are accepted. Text messaging rates may apply.

 Dow 0.00% Nasdaq Up0.52%

Regado Biosciences, Inc. (RGDO)

-NasdaqCM
6.95 Down 0.05(0.71%) 4:00PM EDT
Get the big picture on all your investments.
ProfileGet Profile for:
Regado Biosciences, Inc.
120 Mountain View Boulevard
Basking Ridge, NJ 07920
United States - Map
Phone: 908-580-2100
Website: http://www.regadobio.com

Details 
Index Membership:N/A
Sector:N/A
Industry:N/A
Full Time Employees:28

Business Summary 

Regado Biosciences, Inc., a biopharmaceutical company, focuses on the discovery and development of antithrombotic drug systems for acute and sub-acute cardiovascular and other indications. The company’s lead product includes REG1, an anticoagulant that is in Phase 2b clinical trial for use in patients with various cardiovascular conditions undergoing percutaneous coronary intervention. Its other product candidates under development also comprise REG2, which is in Phase 1 clinical trial for the treatment of venous thrombosis indication; and REG3, a preclinical stage antiplatelet therapy consisting of glycoprotein VI inhibitor for diabetic vasculopathy and other inflammatory diseases. The company was formerly known as Quartet Biosciences, Inc. and changed its name to Regado Biosciences, Inc. in March 2003. Regado Biosciences, Inc. was founded in 2001 and is headquartered in Basking Ridge, New Jersey.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Regado Biosciences, Inc.

Key Executives 
 PayExercised
Dr. David J. Mazzo B.A (Hons), B.Sc. (Hons.), M.Sc., Ph.D., 57
Chief Exec. Officer and Director
689.00K0.00
Mr. Michael A. Metzger MBA, 43
Pres and Chief Operating Officer
178.00K0.00
Dr. Steven L. Zelenkofske M.D., D.O., F.A.C.C., 55
Chief Medical Officer and Sr. VP of Clinical & Medical Affairs
506.00K0.00
Dr. Christopher P. Rusconi Ph.D., 46
Co-Founder, Chief Scientific Officer, Sr. VP of Discovery & Preclinical Devel. and Sec.
N/AN/A
Mr. Christopher E. Courts MBA, CPA, 44
Principal Financial Officer, Principal Accounting Officer and VP of Fin.
N/AN/A
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders